Core Insights - The implementation of the integrated raw material and formulation strategy has significantly enhanced the company's competitiveness and profitability [2] - The company's active pharmaceutical ingredient (API) business revenue saw substantial growth compared to the same period last year [2] - The company is increasing its investment in microbial fermentation innovation to improve production efficiency and product quality [2] Business Strategy - The company is focusing on expanding its domestic and international market presence to boost capacity utilization [2] - Production plans are being arranged based on market demand, ensuring a responsive approach to changing conditions [2] - The company will disclose sales performance of its API business in its annual and semi-annual reports [2]

Group 1 - The core viewpoint of the article highlights the significant growth in the sales revenue of the raw material drug business segment, which has increased by 15 percentage points compared to the same period last year due to the company's integrated strategy of raw materials and formulations [1] - In the veterinary formulations sector, the company is not only consolidating its advantages in the pig medicine business but also actively expanding into poultry, aquaculture, and ruminant sectors, resulting in substantial revenue growth across these product lines [1] - Revenue from pig medicines accounts for approximately 80% of the total revenue from targeted animal categories, indicating a strong reliance on this segment [1]